NCT04868760View on ClinicalTrials.gov

A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab（YERVOY）in Adult Healthy Chinese Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

May 31, 2021

Primary Completion Date

May 2, 2022

Study Completion Date

May 2, 2022

Conditions
Healthy Subjects
Interventions
DRUG

Ipilimumab

Drug: Ipilimumab 0.1 mg/kg and 0.3 mg/kg in preparatory experiments and 0.3 mg/kg in formal experiment.

DRUG

IBI310

Drug: IBI310 0.1 mg/kg and 0.3 mg/kg in preparatory experiments and 0.3 mg/kg in formal experiment.

Trial Locations (1)

Unknown

Huashan Hospital Affiliated to Fudan University, Shanghai

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY